FDA Approves First Functional Cure for Chronic Hepatitis B
Bepirovirsen, branded Hibsago, approved after trials found the virus stayed undetectable for at least 24 weeks after treatment in responders
The US Food and Drug Administration has approved bepirovirsen, a drug developed by GSK and branded as Hibsago, for the treatment of chronic hepatitis B. GSK describes it as the first “functional cure” for the disease, offering some patients the potential to maintain control of the virus after treatment ends.